<DOC>
	<DOCNO>NCT01516476</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multi-center study evaluate efficacy safety RO6807952 patient diabetes mellitus type 2 inadequately control metformin alone . Patients randomize receive dos RO6807952 , placebo , liraglutide . The anticipated time study treatment 12 week .</brief_summary>
	<brief_title>Study RO6807952 Patients With Diabetes Mellitus Type 2</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Adult patient &gt; /= 18 &lt; /=70 year age Diagnosis diabetes mellitus , type 2 least 3 month Treated stable dose metformin Hemoglobin A1c &gt; /=7.0 % &lt; /=10.5 % screen Fasting plasma glucose &lt; /=240 mg/dL screen Body mass index &gt; /=27 kg/m2 &lt; /=42 kg/m2 screen Willing able maintain exist diet exercise habit throughout study Cpeptide &gt; 1.5 ng/mL screen History significant liver kidney disease History uncontrolled hypertension History significant cardiovascular disease History significant diabetic complication History significant gastrointestinal condition History weight loss surgery procedures involve gastrointestinal tract History chronic acute pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>